Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The "multiple endogenous metabolic enzymes and transporters handling ornithine and alpha-ketoglutarate" refers to a collective metabolic network essential for nitrogen homeostasis and energy metabolism. Central to this system is the enzyme ornithine aminotransferase (OAT) [UniProt: P04181], which facilitates the transamination between ornithine and alpha-ketoglutarate to produce glutamate and proline, and transporters such as the mitochondrial ornithine transporter (ORNT1/SLC25A15) [UniProt: Q9Y619], which is vital for urea cycle flux. This network plays a critical role in detoxifying ammonia by converting it into urea or glutamine and provides precursors for the synthesis of polyamines necessary for tissue repair and growth [PubMed: 10959514]. Therapeutic agents like ornithine alpha-ketoglutarate (OKG) leverage these endogenous pathways to treat hyperammonemia in liver disease and to counteract muscle wasting in catabolic states such as severe burns or malnutrition [PubMed: 21114401]. Because this target description encompasses an entire metabolic axis rather than a single protein, it is classified as a pathway-level intervention site rather than a discrete molecular target.
Ornithine alpha-ketoglutarate (OKG) acts as a metabolic substrate that enhances nitrogen clearance and anabolic signaling. Ornithine enters the urea cycle to facilitate the conversion of toxic ammonia into urea and serves as a precursor for the synthesis of glutamine, proline, and polyamines [PubMed: 10959514]. Alpha-ketoglutarate acts as a nitrogen scavenger by reacting with ammonia to form glutamate and subsequently glutamine, while also serving as a key intermediate in the tricarboxylic acid (TCA) cycle to support cellular energy production [PubMed: 21114401]. Together, these components reduce systemic ammonia levels and promote protein synthesis in catabolic states.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ornithine and alpha-ketoglutarate metabolic pathway.